Aventis Lovenox Generics Defense Includes Re-Issuance Of Patent
Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30
Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30